cOASIS, The Online Abstract Submission System 08.01.

24, 13:00

Print this Page for Your Records Close Window

Control/Tracking Number: 2024-A-3912-Diabetes

Activity: Abstract
Current Date/Time: 1/8/2024 12:59:49 PM

iCan CGM System - performance evaluation of a new CGM system with an innovative sensor technology

Author Block: LINONG JI, FRANK FLACKE, FEI GAO, YUANYUAN YU, JIYUN ZHENG, AO GAO, JIANGFENG FEI, Beijing, China,
Mainz, Germany, Changsha, China

Abstract:
Introduction and Objectives. The iCan CGM system, developed by Sinocare Meditech Inc. is equipped with an innovative
sensor technology. Data presented here are from a multicenter study which assessed accuracy of the iCan CGM system;
conducted in China according to international standards and which resulted in regulatory submission. The iCan CGM
system received regulatory clearance 2023 in People’s Republic of China and EU for a wear time of 15 days. Methods. The
study had a single arm, prospective multicenter design and evaluated the iCan CGM system in one of 2 subgroups. There
were 60 patients with T1D and T2D aged ≥18yrs enrolled into this subgroup and at days 2, 7-9 and 15 the performance
of the device was assessed by comparison to YSI readings. The data were analyzed according to generally accepted
procedures. Results. For per protocol set (PPS) the surveillance error grid analysis shows 100% of the data pairs in the
none to slightly lower/higher degree of risk zones (none 94.12% (95%CI: 86.96% - 100%), slightly lower 5.76% (95%CI: 0%
- 12.86%), slightly higher 0.12% (95%CI: 0% - 1.15%). Also, the Clarke error grid confirms this high correlation with the
reference method with 99.22% (95%CI: 98.67% - 99.58%) in Zones A+B. The full analysis set (FAS) analysis shows a MARD
8.88% (95%CI: 7.98% - 9.77%) which is similar the previously reported MARD of 8.71% (95%CI: 7.86 - 9.55%) from the PPS
analysis, and stays below a MARD of 8% for the complete wear life. The average wear life was estimated to 14.76 (1.26)
days. There were no SAEs, devices related AEs and no skin related AEs reported during the study. Conclusion. The iCan
CGM system, becoming available on the worldwide markets, demonstrated in a multicenter trial overall accuracy
performance on par with established devices, high EGA correlation as well as single digit MARD throughout 15 days, in
combination with an outstanding sensor wear life. (NCT0599575)

Category (Complete): 13-B New Technology—Glucose Monitoring and Sensing

Presentation Preference (Complete): Oral Preferred
Financial Support (Complete):
* ADA Support: No

Payment (Complete): Your credit card order has been processed on Sunday 7 January 2024 at 5:19 PM.
Status: Complete

American Diabetes Association

2451 Crystal Drive, Suite 900
Arlington, VA 22202

For questions regarding the abstract submission process, email abstracts@diabetes.org

For Technical Support please contact cOASIS Helpdesk at diabetes@support.ctimeetingtech.com or 217-398-1792

between the hours of 7:00 AM and 6:00 PM (CT) Monday through Friday.

 Feedback

Powered by cOASIS, The Online Abstract Submission and Invitation System SM

© 1996 - 2024 CTI Meeting Technology All rights reserved. Privacy Policy

https://www.abstractsonline.com/cSubmit/SubmitPrinterFrie…&MKey=%7BCF33DE92%2D962D%2D476E%2D94CF%2D062ED8881606%7D Seite 1 von 1